Evolus, Inc. (EOLS)
USD 10.48
(0.92%)
USD 10.48
(0.92%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -41.81 Million USD | 49.17% |
| 2022 | -60.72 Million USD | 7.44% |
| 2021 | -39.05 Million USD | -8.9% |
| 2020 | -144.75 Million USD | 36.51% |
| 2019 | -92.1 Million USD | -102.43% |
| 2018 | -46.13 Million USD | -299.11% |
| 2017 | -11.5 Million USD | 41.41% |
| 2016 | -19.64 Million USD | 35.74% |
| 2015 | -30.56 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -5.78 Million USD | -10.92% |
| 2024 Q2 | -4.67 Million USD | 23.8% |
| 2023 Q4 | -3.56 Million USD | 81.6% |
| 2023 FY | - USD | 49.17% |
| 2023 Q1 | -10.56 Million USD | -11.84% |
| 2023 Q2 | -9.03 Million USD | 14.53% |
| 2023 Q3 | -19.37 Million USD | -114.5% |
| 2022 Q2 | -20.32 Million USD | -41.65% |
| 2022 Q1 | -14.34 Million USD | 16.19% |
| 2022 FY | - USD | 7.44% |
| 2022 Q4 | -9.44 Million USD | 43.77% |
| 2022 Q3 | -16.8 Million USD | 17.32% |
| 2021 FY | - USD | -8.9% |
| 2021 Q4 | -17.12 Million USD | 5.01% |
| 2021 Q1 | -15.28 Million USD | 32.73% |
| 2021 Q2 | -13.38 Million USD | 12.44% |
| 2021 Q3 | -18.02 Million USD | -34.65% |
| 2020 Q3 | -6.82 Million USD | 50.86% |
| 2020 FY | - USD | 36.51% |
| 2020 Q4 | -22.72 Million USD | -233.0% |
| 2020 Q1 | -15.1 Million USD | -41.15% |
| 2020 Q2 | -13.88 Million USD | 8.04% |
| 2019 FY | - USD | -102.43% |
| 2019 Q4 | -10.7 Million USD | 54.07% |
| 2019 Q3 | -23.29 Million USD | 31.68% |
| 2019 Q2 | -34.1 Million USD | -41.04% |
| 2019 Q1 | -24.17 Million USD | -96.51% |
| 2018 Q3 | -9.18 Million USD | -16.34% |
| 2018 Q2 | -7.89 Million USD | -53.47% |
| 2018 Q4 | -12.3 Million USD | -33.93% |
| 2018 FY | - USD | -299.11% |
| 2018 Q1 | -5.14 Million USD | -80.02% |
| 2017 Q3 | -2.61 Million USD | -20.66% |
| 2017 FY | - USD | 41.41% |
| 2017 Q2 | -2.16 Million USD | 43.92% |
| 2017 Q4 | -2.85 Million USD | -9.25% |
| 2017 Q1 | -3.86 Million USD | -7.3% |
| 2016 FY | - USD | 35.74% |
| 2016 Q1 | -5.99 Million USD | 0.0% |
| 2016 Q2 | -5.99 Million USD | 0.0% |
| 2016 Q3 | -4.04 Million USD | 32.49% |
| 2016 Q4 | -3.6 Million USD | 10.97% |
| 2015 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Alvotech | -484.86 Million USD | 91.377% |
| Collegium Pharmaceutical, Inc. | 308.32 Million USD | 113.56% |
| Journey Medical Corporation | 1.92 Million USD | 2276.471% |
| Dynavax Technologies Corporation | 9.66 Million USD | 532.547% |
| Intra-Cellular Therapies, Inc. | -158.85 Million USD | 73.68% |
| PainReform Ltd. | -9.56 Million USD | -336.932% |
| Sunshine Biopharma, Inc. | -3.82 Million USD | -993.238% |
| SCYNEXIS, Inc. | 73.47 Million USD | 156.901% |
| Silver Spike Investment Corp. | 7.34 Million USD | 669.61% |
| Sunshine Biopharma, Inc. | -3.82 Million USD | -993.238% |
| Bright Green Corporation | - USD | Infinity% |
| Esperion Therapeutics, Inc. | -150.1 Million USD | 72.147% |
| Aquestive Therapeutics, Inc. | 1.18 Million USD | 3637.225% |
| ANI Pharmaceuticals, Inc. | 109.32 Million USD | 138.246% |
| Alpha Teknova, Inc. | -25.53 Million USD | -63.71% |
| Embecta Corp. | 245.4 Million USD | 117.037% |
| Safety Shot Inc | -12.18 Million USD | -243.122% |
| Procaps Group, S.A. | 104.02 Million USD | 140.191% |
| Cosmos Health Inc. | -17.06 Million USD | -145.05% |
| China SXT Pharmaceuticals, Inc. | -2.35 Million USD | -1678.385% |
| Pacira BioSciences, Inc. | 162.89 Million USD | 125.667% |
| Theratechnologies Inc. | -10.31 Million USD | -305.419% |
| Harrow Health, Inc. | 9.72 Million USD | 530.011% |
| Sonoma Pharmaceuticals, Inc. | -4.52 Million USD | -823.978% |
| Biofrontera Inc. | -18.45 Million USD | -126.576% |
| DURECT Corporation | -24.68 Million USD | -69.381% |
| Supernus Pharmaceuticals, Inc. | 98.26 Million USD | 142.55% |
| Cronos Group Inc. | -72.14 Million USD | 42.05% |
| OptiNose, Inc. | -15.55 Million USD | -168.823% |
| Ironwood Pharmaceuticals, Inc. | -924.86 Million USD | 95.479% |
| Kala Pharmaceuticals, Inc. | -36.08 Million USD | -15.875% |
| RedHill Biopharma Ltd. | 26.26 Million USD | 259.178% |
| Organogenesis Holdings Inc. | 36.03 Million USD | 216.039% |
| Guardion Health Sciences, Inc. | -3.92 Million USD | -965.942% |
| Cumberland Pharmaceuticals Inc. | -710.85 Thousand USD | -5781.691% |
| Radius Health, Inc. | 38.31 Million USD | 209.136% |
| Universe Pharmaceuticals INC | -3.21 Million USD | -1200.439% |
| ProPhase Labs, Inc. | -14.82 Million USD | -181.986% |
| Phibro Animal Health Corporation | 84.6 Million USD | 149.417% |
| Procaps Group S.A. | 104.02 Million USD | 140.191% |
| TherapeuticsMD, Inc. | -8.4 Million USD | -397.679% |
| Viatris Inc. | 3.51 Billion USD | 101.189% |
| Rockwell Medical, Inc. | -4.69 Million USD | -790.712% |
| Aytu BioPharma, Inc. | -1.01 Million USD | -4031.423% |
| SIGA Technologies, Inc. | 84.15 Million USD | 149.68% |
| Tilray Brands, Inc. | -72.84 Million USD | 42.603% |
| Lifecore Biomedical, Inc. | 812 Thousand USD | 5249.015% |
| Shineco, Inc. | -26.55 Million USD | -57.453% |
| PetIQ, Inc. | 81.48 Million USD | 151.309% |
| Regencell Bioscience Holdings Limited | -3.61 Million USD | -1055.73% |
| Incannex Healthcare Limited | -18.5 Million USD | -125.951% |
| Neurocrine Biosciences, Inc. | 416.1 Million USD | 110.048% |
| Alimera Sciences, Inc. | 7.27 Million USD | 674.629% |
| Assertio Holdings, Inc. | -222.44 Million USD | 81.205% |
| Shuttle Pharmaceuticals Holdings, Inc. | -3.99 Million USD | -947.699% |
| Petros Pharmaceuticals, Inc. | -4.21 Million USD | -892.67% |
| Clever Leaves Holdings Inc. | -16.8 Million USD | -148.81% |
| Cyclo Therapeutics, Inc. | -20.03 Million USD | -108.729% |
| Avadel Pharmaceuticals plc | -149.12 Million USD | 71.963% |
| Hempacco Co., Inc. | -12.77 Million USD | -227.324% |
| Talphera, Inc. | -9.84 Million USD | -324.812% |
| Alvotech | -484.86 Million USD | 91.377% |
| Eagle Pharmaceuticals, Inc. | 77.5 Million USD | 153.947% |
| Lantheus Holdings, Inc. | 491 Million USD | 108.515% |
| Currenc Group, Inc. | -1.9 Million USD | -2099.862% |
| Kamada Ltd. | 21.53 Million USD | 294.158% |
| Indivior PLC | 66 Million USD | 163.348% |
| Evoke Pharma, Inc. | -7.29 Million USD | -473.345% |
| Flora Growth Corp. | -45.87 Million USD | 8.851% |
| Cyclo Therapeutics, Inc. | -20.03 Million USD | -108.729% |
| HUTCHMED (China) Limited | 25.52 Million USD | 263.781% |
| Amphastar Pharmaceuticals, Inc. | 241.46 Million USD | 117.315% |
| Akanda Corp. | -27.73 Million USD | -50.744% |